| |
| |
|
| Insider
Information: |
Yea Christopher |
| Relationship: |
|
| City: |
Salisbury, Wiltshire |
| State: |
X0 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
72,895 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$879,114 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
72,895 |
|
|
| Total
Value |
$879,114 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
8
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
1.7
|
| Percentage
Gain/Loss : |
0.0%
|
 160.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Kalvista Pharmaceuticals Inc |
KALV |
|
2024-02-20 |
72,895 |
2016-11-21 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KALV |
Kalvista Pharmaceuticals ... |
CHIEF DEVELOPMENT OFFICER |
• – – |
2024-02-20 |
4 |
S |
$14.11 |
$170,124 |
D/D |
(12,053) |
72,895 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
CHIEF DEVELOPMENT OFFICER |
• – – |
2024-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,788 |
84,948 |
0 |
- |
|
| KALV |
Kalvista Pharmaceuticals ... |
CHIEF DEVELOPMENT OFFICER |
• – – |
2024-02-14 |
4 |
S |
$15.01 |
$598,661 |
D/D |
(39,886) |
66,160 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
CHIEF DEVELOPMENT OFFICER |
• – – |
2024-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
106,046 |
0 |
- |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2023-11-20 |
4 |
S |
$8.23 |
$58,535 |
D/D |
(7,113) |
46,046 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2023-11-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,497 |
53,159 |
0 |
- |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2023-08-18 |
4 |
S |
$10.73 |
$76,624 |
D/D |
(7,142) |
41,662 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2023-08-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,494 |
48,804 |
0 |
- |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2023-05-18 |
4 |
S |
$10.14 |
$26,416 |
D/D |
(2,604) |
37,310 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,205 |
39,914 |
0 |
- |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2023-02-17 |
4 |
S |
$7.66 |
$20,889 |
D/D |
(2,727) |
35,709 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2023-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,204 |
38,436 |
0 |
- |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2022-11-18 |
4 |
S |
$5.44 |
$6,196 |
D/D |
(1,139) |
34,232 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2022-11-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,774 |
35,371 |
0 |
- |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2022-08-17 |
4 |
S |
$14.96 |
$17,130 |
D/D |
(1,145) |
33,597 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2022-08-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,773 |
34,742 |
0 |
- |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2021-11-01 |
4 |
AS |
$18.07 |
$90,328 |
D/D |
(5,000) |
32,969 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2021-08-02 |
4 |
AS |
$20.52 |
$102,579 |
D/D |
(5,000) |
37,969 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2021-05-03 |
4 |
AS |
$24.84 |
$124,197 |
D/D |
(5,000) |
42,969 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2021-02-23 |
4 |
AS |
$31.87 |
$503,877 |
D/D |
(15,000) |
47,969 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2020-10-29 |
4 |
AS |
$17.48 |
$87,394 |
D/D |
(5,000) |
62,969 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2020-10-21 |
4 |
AS |
$17.68 |
$110,282 |
D/D |
(6,044) |
67,969 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2020-10-20 |
4 |
AS |
$17.27 |
$138,886 |
D/D |
(7,942) |
74,013 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2020-10-16 |
4 |
AS |
$17.00 |
$15,539 |
D/D |
(914) |
81,955 |
0 |
% |
|
| KALV |
Kalvista Pharmaceuticals ... |
Chief Development Officer |
• – – |
2020-02-05 |
4 |
AS |
$17.10 |
$1,710 |
D/D |
(100) |
82,869 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
